WJ-39

• Description:

  WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.WJ-39 inhibits oxidative stress and inhibits the activation of the inflammatory vesicle of the oligomerization structural domain-like receptor family, pyrin structural domain 3 (NLRP3) .

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  430.32

• Molecular Formula:

  C19H14Cl2KNO4

• Notes:

  Research use only, not for human use.

• Receptor:

  Reductase

• CAS Number:

  3009908-95-3